Rilpivirine

Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI) . Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM) . Rilpivirine has a high genetic barrier to resistance development of HIV[1][2].

Product Specifications

CAS Number

[500287-72-9]

Product Name Alternative

R278474; TMC278; DB08864

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Rilpivirine.html

Purity

99.67

Solubility

DMSO : 18.18 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCL; heat to 60°C)

Smiles

CC1=CC(/C=C/C#N)=CC(C)=C1NC2=CC=NC(NC3=CC=C(C=C3)C#N)=N2

Molecular Formula

C22H18N6

Molecular Weight

366.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Janssen PAJ, et, al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[ (1E) -2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) . J Med Chem. 2005 Mar 24;48 (6) :1901-9.|[2]Azijn H, et, al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010 Feb;54 (2) :718-27.